United States Patent US 8,399,015: Solid Dispersions of Lopinavir/Ritonavir Using Tg-Qualified Water-Soluble Polymers and HLB-Qualified Surfactants

US 8,399,015 is directed to solid pharmaceutical dosage forms that embed lopinavir and ritonavir (and also ritonavir alone) in a solid dispersion that is defined by two independent formulation constraints:
1) a water-soluble polymer with Tg ≥ 50°C, and
2) a surfactant with HLB from 4 to 10, with multiple dependent claim paths narrowing polymer identity (e.g., copovidone; PV (N-vinyl pyrrolidone)/vinyl acetate copolymer), surfactant identity (sorbitan fatty acid esters; sorbitan monolaurate), and performance/quality metrics (dog non-fasting dose-adjusted AUC thresholds; ritonavir content retention after stability stress).

What is the claim core (what is actually protected)?

At the broadest level, the patent protects a formulation concept, not a process. The central claim theme is a solid dispersion (solid solution or glassy solution) of protease inhibitors where the matrix is controlled by polymer glass transition temperature (Tg) and surfactant HLB.

Independent claim sets (substance of scope)

From the provided claim text, the patent contains three “platform” formulations:

Lopinavir + ritonavir in a Tg-Qualified polymer / HLB-Qualified surfactant solid dispersion
- Claim 1: solid dosage form comprising a solid dispersion including lopinavir and ritonavir, water-soluble polymer Tg ≥ 50°C, and surfactant HLB 4–10.
- Claim 12: same concept but allows the use of combinations of Tg-qualified water-soluble polymers and/or combinations of HLB-4-to-10 surfactants.
Ritonavir alone in the same platform system
- Claim 18: solid dosage form comprising a solid dispersion including ritonavir, water-soluble polymer Tg ≥ 50°C, and surfactant HLB 4–10.
- Claim 28: same concept allowing polymer/surfactant combinations.
Shared narrowing claim architecture
- “Solid solution or glassy solution” appears as a narrowing element (claims 6–7, 15, 19, 21–22, 29).
- Material composition ranges appear as additional narrowing in claims 11 and 25, tied to polymer % and surfactant %.

Key definitional levers that control infringement risk

These are the three technical levers that determine whether a competitor’s formulation falls inside the literal claim language:

Drug scope
- Claim 1/12 protect lopinavir + ritonavir together.
- Claim 18/28 protect ritonavir alone.
Polymer Tg
- Polymer must be water-soluble and have Tg ≥ 50°C.
- Dependent claim 8 adds an upper/lower tightening: Tg 80–180°C.
Surfactant HLB
- Surfactant(s) must have HLB 4 to 10.
- Dependent claims lock in specific surfactant chemistries like sorbitan fatty acid esters and specifically sorbitan monolaurate.

How broad are Claims 1 and 12 vs the dependent claim lattice?

US 8,399,015 uses a classic broad-to-narrow hierarchy: independent claims establish the concept; dependent claims lock in specific polymer and surfactant types and then add functional performance and stability constraints.

Claim 1 (broad base)

Claim 1: A solid pharmaceutical dosage form comprising a solid dispersion with:

lopinavir and ritonavir
water-soluble polymer Tg ≥ 50°C
surfactant HLB 4–10

This is broad because it does not require a particular polymer identity, nor does it require a particular surfactant identity, so long as Tg and HLB constraints are met.

Claim 12 (broad base with explicit “combination” allowance)

Claim 12: similar platform, but expressly permits:

combinations of water-soluble polymers (each with Tg ≥ 50°C, or where the combination is itself within the “Tg ≥ 50°C” requirement as written)
combinations of surfactants with HLB 4–10

This claim reduces “design-around” leverage based on argument that the formulation uses more than one polymer or surfactant.

Dependent narrowing that creates “safe harbor” zones

Dependent claims 2–5, 3–5, 8–11, 16–17, and 9–10 impose additional constraints that competitors must avoid if they are pursuing closer-to-marketing equivalents.

Notably, the patent includes both:

formulation-identity limitations (polymer chemistry; surfactant chemistry), and
performance and stability limitations tied to dog non-fasting AUC and ritonavir retention.

What polymer chemistries are explicitly covered?

The patent explicitly names three polymer pathways:

1) Copovidone

Claim 4: water-soluble polymer is copovidone
Claim 13: combination of Tg-qualified polymers
Claim 27: copovidone + sorbitan monolaurate

2) PV (N-vinyl pyrrolidone) / vinyl acetate copolymer

Claim 3: copolymer of N-vinyl pyrrolidone and vinyl acetate
Claim 5 and 26: that copolymer in combination with sorbitan fatty acid ester surfactants

3) Tg-qualified water-soluble polymers generally

Embedded in claims 1, 12, 18, 28
Dependent constraint: Claim 8 requires Tg of 80 to 180°C

Implication for landscape mapping: any competitor polymer choice is inside claim scope if it is (i) water-soluble and (ii) has Tg ≥ 50°C, even if it is not named, unless an exclusion is found through claim construction, evidence of non-water-solubility, or Tg measurement methodology arguments (not addressed in the provided claim text).

What surfactants are explicitly covered, and how does HLB 4–10 work in practice?

The claims use two layers:

Broad layer (identity-agnostic)

Surfactant must have HLB 4 to 10 (claims 1, 12, 18, 28).

Specific surfactant chemistries

Claim 2: sorbitan fatty acid ester
Claim 20: surfactant is a sorbitan fatty acid ester
Claim 22 and 27: surfactant is sorbitan monolaurate
Claims 5, 21, 26 tie specific surfactant class/identity to specific polymer types

Competition relevance: if a competitor uses a surfactant with HLB outside 4–10, the formulation can be outside the literal claim scope for the HLB element. If it uses a surfactant inside 4–10 but changes away from sorbitan-type chemistry, it may still land inside the independent claims unless it also changes Tg or polymer identity in a way that removes “water-soluble polymer Tg ≥ 50°C” compliance.

How do performance claims expand or narrow practical infringement?

Claims 9, 16, and 23 introduce dog non-fasting pharmacokinetic metrics, and claims 10 and 17 introduce stability content retention.

Dog non-fasting dose-adjusted AUC thresholds

Claim 9 (for Claim 1 platform; lopinavir + ritonavir):
- dose-adjusted AUC (dogs, non-fasting) of ritonavir ≥ 9 μg·h/mL/100 mg
- dose-adjusted AUC (dogs, non-fasting) of lopinavir ≥ 20 μg·h/mL/100 mg
Claim 16 (for Claim 12 platform; combination polymers/surfactants): same thresholds
Claim 23 (for Claim 18 platform; ritonavir):
- dose-adjusted AUC (dogs, non-fasting) of ritonavir ≥ 9 μg·h/mL/100 mg

These claims convert the formulation into a “by performance” boundary. A competitor that meets the formulation elements but misses the AUC thresholds may still avoid those dependent claims, but the independent claims may still capture the formulation if the independent elements are present.

Storage stability content retention

Claim 10 (for Claim 1 platform): after 6 weeks at 40°C and 75% humidity, contains at least 98% of initial ritonavir content
Claim 17 (for Claim 12 platform): same
(No analogous dependent stability claim is listed in the provided text for Claim 18/28, but there is a matching “ritonavir retention” concept embedded in the lopinavir/ritonavir claim family via claims 10 and 17.)

Competition relevance: stability-dependent claims can matter most when litigating obviousness, but for literal infringement they can be decisive for dependent claim coverage.

What composition ratios are explicitly constrained?

Claims 11 and 25 impose material percentage ranges.

Claim 11 (on Claim 1):
- water-soluble polymer: 50 to 85% by weight
- surfactant: 2 to 20% by weight
Claim 25 (on Claim 12): same ranges
Claim 31 (on Claim 29):
- water-soluble polymer or polymer combination: 50 to 85% by weight
- surfactant or surfactant combination: 2 to 20% by weight

These constraints may be the most actionable design parameters for competitors trying to move out of dependent claim coverage while staying close to independent claim scope.

Where do the “solid solution or glassy solution” limitations land?

Multiple dependent claims narrow the physical state of the dispersion:

Claim 6 and 7: solid dispersion is solid solution or glassy solution
Claim 15: same for Claim 12
Claims 19: solid solution or glassy solution for ritonavir
Claim 21 and 29: consistent narrowing in respective branches

If a competitor develops a different dispersion morphology (e.g., crystalline dispersion, eutectic mixture, amorphous dispersion that does not meet “solid solution or glassy solution” characterization), that could remove coverage for these dependent claims, but again independent claims may still capture if “solid dispersion” is construed broadly enough and if physical-state characterization evidence aligns.

Claim-by-claim landscape map (scope grid)

Core protected subject matter

Dimension	Broad coverage (independent)	Dependent claim narrowing (examples)
Drug(s)	Lopinavir + ritonavir (Claims 1, 12); ritonavir alone (Claims 18, 28)	AUC/stability depend on the branch (Claims 9–10, 16–17, 23)
Solid dispersion type	Solid dispersion in a solid pharmaceutical dosage form	“Solid solution or glassy solution” (Claims 6–7, 15, 19, 29)
Polymer	Water-soluble polymer Tg ≥ 50°C	Tg 80–180°C (Claim 8); copovidone (Claim 4); PV/vinyl acetate copolymer (Claim 3)
Surfactant	HLB 4–10	sorbitan fatty acid ester (Claims 2, 20); sorbitan monolaurate (Claims 22, 27)
Polymer/surfactant proportions	Not specified in independents	Polymer 50–85 wt%; surfactant 2–20 wt% (Claims 11, 25, 31)
Performance & stability	Not required in independents (as written)	Dog non-fasting AUC thresholds (Claims 9, 16, 23) and ritonavir stability retention (Claims 10, 17)

How does the patent structure affect “design-around” strategy?

Using only the provided claim text, design-around levers fall into three buckets:

Bucket A: Alter polymer Tg or water solubility

Move polymer below Tg 50°C or remove the “water-soluble polymer” condition to exit independent claim scope.
Dependent claims can also be avoided by targeting Tg outside 80–180°C (Claim 8), but that alone may not avoid independent claims.

Bucket B: Alter surfactant HLB or surfactant combination

Use surfactant(s) with HLB outside 4–10 to exit independent claim scope.
Note: Claims 12 and 28 allow combinations, so “mixing” to achieve an average HLB is less effective if the claim construction evaluates actual surfactant HLB values rather than a weighted average.

Bucket C: Alter drug inclusion or dispersion state

The lopinavir+ritonavir branch is not covered if lopinavir is absent; but ritonavir-only claims remain.
Physical state changes may avoid dependent coverage (“solid solution or glassy solution”) but may not avoid independent “solid dispersion” if construed broadly.

What does this imply for the patent landscape around HIV protease inhibitor solid dispersions?

Even without the rest of the US filing history and related patents, the claim set itself defines a specific formulation methodology that typically sits among a cluster of patents for:

supersaturating delivery systems,
amorphous/solid dispersion matrices,
polymer selection by Tg,
surfactant tuning by HLB, and
protease inhibitor-specific PK and stability evidence (dog non-fasting AUC, ritonavir retention under humidity/temperature).

Within a landscape view, US 8,399,015’s novelty boundary (based on claim structure) is the combination of:

Tg-qualified water-soluble polymer selection,
HLB-limited surfactant selection,
solid solution/glassy solution characterization,
and drug-specific PK and stability targets.

Practically, other patents in this area will often overlap on either Tg or surfactant choice, but full overlap is less common because independent claims require both levers simultaneously.

What is the effective claim “coverage perimeter” for competitors?

A competitor that makes and sells a solid dispersion dosage form containing:

lopinavir and ritonavir (or ritonavir alone),
with a water-soluble polymer whose Tg is at least 50°C,
and with a surfactant of HLB 4–10,
in a “solid dispersion” form,

is exposed to the independent claim scope (Claims 1, 12, 18, 28), even if it avoids dependent constraints like:

specific polymer identity (copovidone; PV/vinyl acetate),
specific surfactant identity (sorbitan monolaurate),
solid solution/glassy solution labeling,
specific wt% ratio windows,
dog AUC performance thresholds,
and 40°C/75% RH, 6-week ritonavir retention ≥ 98%.

Conversely, a competitor can reduce dependent-claim risk by missing any of these narrowing elements, but independent claim compliance remains the key exposure point.

Key Takeaways

US 8,399,015 protects solid dispersion dosage forms for lopinavir/ritonavir and ritonavir alone defined by (i) water-soluble polymer Tg ≥ 50°C and (ii) surfactant HLB 4–10.
The most consequential claim elements for landscape and design-around are the Tg threshold and the HLB window; they sit in the independent claims and are not limited to specific polymer/surfactant identities.
Dependent claims add tight coverage for copovidone and N-vinyl pyrrolidone/vinyl acetate copolymers, sorbitan fatty acid esters (including sorbitan monolaurate), polymer 50–85 wt% / surfactant 2–20 wt%, and performance/stability evidence: dog non-fasting dose-adjusted AUC thresholds and ritonavir retention ≥ 98% after 6 weeks at 40°C/75% RH.
Competitors are most likely to mitigate risk by moving formulations outside either the Tg ≥ 50°C condition or the HLB 4–10 condition, because these are present in the independent claim set.

FAQs

1) Does US 8,399,015 require the dispersion to be amorphous?
The claims narrow the dispersion type in dependent claims to “solid solution or glassy solution,” but the independent claims protect “solid dispersion” broadly as written.

2) Is copovidone mandatory to infringe?
No. Copovidone appears in dependent claim coverage (e.g., Claim 4). Independent claims cover any water-soluble polymer with Tg ≥ 50°C.

3) Can a competitor use multiple polymers and multiple surfactants?
Yes. Claims 12 and 28 expressly allow combinations of polymers and combinations of surfactants, as long as the Tg and HLB conditions are satisfied as written.

4) Are dog AUC thresholds required for the broadest protection?
No. The dog AUC thresholds appear in dependent claims (Claims 9, 16, 23). The independent claim scope is defined by formulation elements.

5) Which constraint is most efficient for design-around: Tg or HLB?
Both are independent claim elements. Exiting the HLB 4–10 window or the Tg ≥ 50°C window is the most direct route out of the independent claim perimeter based on the provided language.

Sources

No external sources were provided, and the claim text was supplied directly by the user; therefore no additional citations are included.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	055734	⤷ Start Trial
Argentina	077411	⤷ Start Trial
Australia	2006216856	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,399,015

Summary for Patent: 8,399,015